系统治疗在晚期皮肤鳞状细胞癌中的作用。

The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma.

机构信息

Department of Head and Neck - Endocrine Oncology Program, Moffit Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.

Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, 3400 Bainbridge Avenue, 3rd Floor Medical Arts Pavilion, Bronx, NY 10467, USA; Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, 3400 Bainbridge Avenue, 3rd Floor Medical Arts Pavilion, Bronx, NY 10467, USA.

出版信息

Otolaryngol Clin North Am. 2021 Apr;54(2):343-355. doi: 10.1016/j.otc.2020.11.007. Epub 2021 Feb 11.

DOI:10.1016/j.otc.2020.11.007

PMID:33583597

Abstract

Systemic therapy for patients with head and neck cutaneous squamous cell carcinoma (HNCSCC) generally is used for patients with advanced disease and most often employed for patients in the palliative setting when disease is unresectable and/or widely metastatic. Cytotoxic agents and epidermal growth factor receptor pathway targeted therapy have been utilized most commonly, with few clinical data to support their efficacy. Adjuvant postoperative chemoradiation with platinum has been called into question based on recent data. Programmed cell death protein 1 receptor immune checkpoint inhibitors have demonstrated profound activity in HNCSCC, and cemiplimab and pembrolizumab now are approved for use for unresectable/metastatic disease.

摘要

对于头颈部皮肤鳞状细胞癌（HNCSCC）患者，通常采用全身性治疗，主要针对晚期疾病患者，且当疾病无法切除和/或广泛转移时，通常用于姑息治疗。最常使用细胞毒性药物和表皮生长因子受体通路靶向治疗，但几乎没有临床数据支持其疗效。基于最近的数据，辅助术后含铂放化疗受到质疑。程序性死亡蛋白 1 受体免疫检查点抑制剂在 HNCSCC 中显示出显著的活性，西米普利单抗和帕博利珠单抗现已批准用于不可切除/转移性疾病。